Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Thiopropazate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.70 |
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 0.70 |
| ▸ | ADRA2B known ✓ | P18089 | 5/20 | 0.70 |
| ▸ | ADRA2C known ✓ | P18825 | 5/20 | 0.70 |
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.70 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.70 |
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 0.70 |
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 0.70 |
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 0.70 |
| ▸ | HTR2B known ✓ | P41595 | 5/20 | 0.70 |
| ▸ | HTR1A known ✓ | P08908 | 5/20 | 0.70 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.70 |
| ▸ | ADRA1A known ✓ | P35348 | 4/20 | 0.70 |
| ▸ | SLC6A3 known ✓ | Q01959 | 4/20 | 0.70 |
| ▸ | KCNH2 known ✓ | Q12809 | 4/20 | 0.70 |
| ▸ | DRD1 known ✓ | P21728 | 4/20 | 0.70 |
| ▸ | OPRK1 known ✓ | P41145 | 3/20 | 0.70 |
| ▸ | CHRM5 known ✓ | P08912 | 3/20 | 0.70 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.70 |
| ▸ | HTR6 known ✓ | P50406 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiopropazate SCHEMBL955966 | 1.00 | MAPT (0.70) | MAPTLMNADRD2CYP2D6MAPK1 | |
| Thiopropazate SCHEMBL31153316 | 1.00 | MAPT (0.70) | MAPTLMNADRD2CYP2D6MAPK1 | |
| Thiopropazate SCHEMBL144729 | 0.99 | MAPT (0.72) | MAPTLMNADRD2CYP2D6MAPK1 | |
| Thiopropazate SCHEMBL1651297 | 0.97 | MAPT (0.69) | MAPTLMNADRD2CYP2D6MAPK1 | |
| Thiopropazate SCHEMBL5972306 | 0.96 | DRD2 (0.77) | MAPTLMNADRD2CYP2D6MAPK1 | |
| SCHEMBL13464239 | 0.91 | CYP2D6 (0.73) | MAPTLMNADRD2CYP2D6MAPK1 | |
| SCHEMBL10084511 | 0.89 | DRD2 (0.69) | MAPTLMNADRD2CYP2D6MAPK1 | |
| Thiopropazate SCHEMBL13724873 | 0.89 | MAPT (0.71) | MAPTLMNADRD2CYP2D6MAPK1 | |
| SCHEMBL1041510 | 0.89 | DRD2 (0.68) | MAPTLMNADRD2CYP2D6MAPK1 | |
| SCHEMBL10084508 | 0.88 | DRD2 (0.67) | MAPTLMNADRD2CYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0180364-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOTHIAZINES | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1990-03-07 | — | — | EP | claimed |
| EP-0180364-A2 | Pharmaceutical compositions containing phenothiazines | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1986-05-07 | — | — | EP | claimed |
| US-20210330706-A1 | Children Blood Transfusion and Thymus Hormonal Therapy as Antiviral and Antibacterial Compounds | BATARSEH KAREEM ISSA (US) | 2021-10-28 | — | — | US | disclosed |
| EP-2269595-B1 | Titratable dosage transdermal delivery system | EURO CELTIQUE SA (LU) | 2018-01-31 | — | — | EP | disclosed |
| US-9289397-B2 | Titratable dosage transdermal delivery system | PURDUE PHARMA L.P. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150246006-A1 | TRANSDERMAL SYSTEMS HAVING CONTROL DELIVERY SYSTEM | MYLAN TECHNOLOGIES, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| US-20140303571-A1 | TITRATABLE DOSAGE TRANSDERMAL DELIVERY SYSTEM | PURDUE PHARMA LP (US) | 2014-10-09 | — | — | US | disclosed |
| US-8784880-B2 | Titratable dosage transdermal delivery system | PURDUE PHARMA L.P. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8673366-B2 | Chemotherapeutic and prophylactic pharmaceutical compositions | ALPHA OMEGA BIO FOR DISINFECTANT AND DETERGENT MANUFACTURING (KW) | 2014-03-18 | — | — | US | disclosed |
| EP-2002826-B1 | Titratable dosage transdermal delivery system | EURO CELTIQUE SA (LU) | 2012-08-15 | — | — | EP | disclosed |
| US-20110020450-A1 | TITRATABLE DOSAGE TRANSDERMAL DELIVERY SYSTEM | EURO-CELTIQUE | 2011-01-27 | — | — | US | disclosed |
| EP-0013606-B1 | DRUG DELIVERY DEVICE AND METHOD FOR ITS PREPARATION | Key Pharmaceuticals, Inc. (US) | 1984-05-02 | — | — | EP | disclosed |
| EP-0099122-A2 | Compositions comprising pepstatin and an histamine H2-receptor antagonist having an enhanced antiulcer activity | Bristol-Myers Company (US) | 1984-01-25 | — | — | EP | disclosed |
| EP-0099121-A2 | Pharmaceutical compositions | Bristol-Myers Company (US) | 1984-01-25 | — | — | EP | disclosed |
| EP-0056973-A1 | Pharmaceutical compositions | Bristol-Myers Company (US) | 1982-08-04 | — | — | EP | disclosed |
| US-4339439-A | Pharmaceutical methods and compositions | BRISTOL-MYERS COMPANY (US) | 1982-07-13 | — | — | US | disclosed |
| EP-0040861-A1 | Polymeric diffusion matrix and method of its preparation | Key Pharmaceuticals, Inc. (US) | 1981-12-02 | — | — | EP | disclosed |
| EP-0040862-A1 | Burn matrix, method of its preparation and delivery device comprising said matrix | Key Pharmaceuticals, Inc. (US) | 1981-12-02 | — | — | EP | disclosed |
| EP-0013606-A2 | Drug delivery device and method for its preparation | Key Pharmaceuticals, Inc. (US) | 1980-07-23 | — | — | EP | disclosed |
| US-3996934-A | Medical bandage | ALZA CORPORATION (US) | 1976-12-14 | — | — | US | disclosed |